UNSPSC 51351607: Dydrogesterone

This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90I02KLE8K, chemically known as 9beta,10alpha-pregna-4,6-diene-3,20-dione but generally known as dydrogesterone, which bears US NIH Compound Identifier 9051. European Medicines Agency schedules Dydrogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06433MIG.

UNSPSC 51351607 Dydrogesterone (Commodity) addresses pharmaceutical product procurement, with state and local governments currently buying generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles that consolidate demand across multiple jurisdictions and establish master pricing agreements with manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body sourcing under this code, using cooperative purchasing to serve participating state and local government facilities. Manufacturers responding to this code must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co.), and submit detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations. Pricing structures include fixed price, net price formats (NF30, NF60, NF90), and WAC-minus options, with evaluation weighted heavily toward price competitiveness (75 percent) and compliance with administrative requirements (10 percent), EDI capability (5 percent), and contractual terms (10 percent).

MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802) represents recent activity centered in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. The two-year contract term applies to new responders with optional MMCAP extensions; incumbent vendors' amendments align with existing agreement expiration through June 30, 2028. Vendors must maintain comprehensive insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability, and all products must comply with FDA requirements with expiration dates at least one year from manufacture and minimum six-month shelf life. The solicitation does not disclose specific award values or budget ranges, but vendors should anticipate 3 percent administrative fees on all purchases and performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. Submissions are due through the ePro procurement system by March 26, 2026, with the cutoff for questions on February 18, 2026.